Codexis, Inc. (CDXS) SVP Sells $372,981.35 in Stock
Codexis, Inc. (NASDAQ:CDXS) SVP James Lalonde sold 19,999 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $18.65, for a total transaction of $372,981.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of CDXS traded up $0.19 during mid-day trading on Thursday, reaching $19.56. 12,619 shares of the stock traded hands, compared to its average volume of 393,244. The firm has a market capitalization of $1.08 billion, a P/E ratio of -93.38 and a beta of -0.37. Codexis, Inc. has a 12-month low of $12.85 and a 12-month high of $23.05. The company has a quick ratio of 3.38, a current ratio of 3.42 and a debt-to-equity ratio of 0.51.
Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). The business had revenue of $15.58 million during the quarter, compared to analyst estimates of $14.83 million. Codexis had a negative net margin of 18.22% and a negative return on equity of 21.08%. Equities analysts expect that Codexis, Inc. will post -0.23 earnings per share for the current fiscal year.
Several brokerages recently weighed in on CDXS. BidaskClub raised shares of Codexis from a “hold” rating to a “buy” rating in a research note on Tuesday, May 7th. ValuEngine upgraded shares of Codexis from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Zacks Investment Research upgraded shares of Codexis from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Thursday, January 17th. Craig Hallum lifted their price objective on shares of Codexis from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, February 27th. Finally, HC Wainwright lifted their price objective on shares of Codexis to $22.50 and gave the company a “buy” rating in a research note on Monday, March 4th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has an average rating of “Buy” and an average price target of $21.07.
WARNING: This piece was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.mareainformativa.com/news/2019/05/16/codexis-inc-cdxs-svp-sells-372981-35-in-stock.html.
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Featured Article: How to track put option volume
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.